Keeping Track: US FDA Clears Santen’s Omlonti, Fennec’s Pedmark; Lilly’s Retevmo Adds Tumor-Agnostic Claim

 
• By Bridget Silverman

The latest drug approval news and highlights from the Pink Sheet’s US FDA Performance Tracker

Keeping Track Feature image

More from US FDA Performance Tracker

More from Regulatory Trackers